Company news
Organon & Co. (NYSE:OGN) news
Every Organon & Co. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
September 14, 2026
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
August 11, 2026
Organon Announces Quarterly Dividend
July 31, 2026
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Der...
July 24, 2026
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
July 16, 2026
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
July 7, 2026
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab in...
June 23, 2026
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
June 22, 2026
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in...
June 18, 2026
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Synd...
June 10, 2026
Organon to Present New Research on Access and Value at ISPOR 2026
May 15, 2026
Organon Reports Results for the First Quarter Ended March 31, 2026
April 30, 2026
Organon Cancels First Quarter Earnings Call
April 29, 2026
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in E...
April 29, 2026
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in E...
April 29, 2026
Sun Pharma signs Definitive Agreement to Acquire Organon
April 26, 2026
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
April 16, 2026
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatri...
April 15, 2026
Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants
March 29, 2026
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and It...
March 27, 2026
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Su...
February 27, 2026
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
February 23, 2026
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
February 12, 2026
Organon Launches Third Edition of Women's Health Accelerator Program Across Middle East, Turkey & Africa
February 4, 2026
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
January 29, 2026
Organon Completes Divestiture of JADA® System to Laborie
January 28, 2026
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON(R)...
January 19, 2026
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (...
January 16, 2026
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
January 8, 2026
TetraScience and Organon Collaborate to Modernize Quality Control Data Management
December 16, 2025
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
November 17, 2025
Organon Reports Results for the Third Quarter Ended September 30, 2025
November 10, 2025
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those ...
November 8, 2025
Laborie Announces Agreement to Acquire the JADA® System from Organon
November 7, 2025
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
November 7, 2025
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
November 6, 2025
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Au...
October 27, 2025
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab...
September 19, 2025
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimila...
September 2, 2025
Organon Reports Results for the Second Quarter Ended June 30, 2025
August 5, 2025
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
July 22, 2025
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for ...
July 7, 2025
Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain
July 2, 2025
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Inj...
May 27, 2025
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
April 15, 2025
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
April 15, 2025
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion...
April 1, 2025
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
March 28, 2025
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment...
March 8, 2025